Although there are many examples throughout history of positive changes in top company management teams, important personnel moves tend to unsettle investors. They get worried that significant changes could reflect instability, indecision, or both in a company's decision-making. That seemed to be very much the case Monday with biotech Scholar Rock(NASDAQ: SRRK). Its stock closed almost 4% lower in price on a day when the S&P 500 index basically traded flat. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » A quartet of new executive appointments Scholar Rock's C-suite now looks radically different, as the company brought in a clutch of new top managers. The incoming CEO is David Hallal, the chairman of the company's board. As CEO, he succeeds Jay Backstrom, who is transitioning into a role as strategic advisor. Hallal served in several managerial positions with Scholar Rock's peer, Alexion, including CEO, before joining Scholar Rock's board in 2017. There will be three other high-level executives reporting to him. R. Keith Woods is now the company's chief operating officer, Vikas Sinha -- also an Alexion veteran -- is chief financial officer, and Akshay Vaishnaw is president of research and development (a crucial position in clinical-stage biotechs like Scholar Rock). Nothing to see here? It's doubtful that investors are concerned about the qualifications and/or expertise of the new Scholar Rock management, given their distinguished histories. The concern is that a very significant set of changes was made all at once; I'd hardly fault them for feeling that way. As far as we know, Scholar Rock isn't particularly in trouble in any way, but investors should certainly keep an eye on the company's press releases and regulatory disclosures in the coming days and weeks. Should you invest $1,000 in Scholar Rock right now? Before you buy stock in Scholar Rock, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Scholar Rock wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider whenNetflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you’d have $594,046!* Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation,you’d have $680,390!* Now, it’s worth notingStock Advisor’s total average return is872% — a market-crushing outperformance compared to160%for the S&P 500. Don’t miss out on the latest top 10 list, available when you joinStock Advisor. See the 10 stocks » Story Continues *Stock Advisor returns as of April 28, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Scholar Rock Stock Took a Knock on Monday was originally published by The Motley Fool View Comments
Why Scholar Rock Stock Took a Knock on Monday
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...